Pharma Focus Asia

Minaris Regenerative Medicine Opens New Manufacturing Sites in Europe and Asia


Minaris Regenerative Medicine plans to invest US$64.5 million to open new manufacturing facilities in Asia and Europe. This expansion increases the cell and gene manufacturing capabilities.


The project laid with an investment of US$64.5 million will expand the manufacturing sites of both Europe and Asia.

European Facility Expansion:
The European facility constructed with an US$40.7 million will cover an area of 6,650 sqm. This additional investment doubles the size of the existing capacity in Europe by further adding clean rooms, quality control laboratories, warehousing, cryo-storage, and office space.

European new state of the art facility will be constructed adjacent to the existing site in Ottobrunn near Munich.

The new manufacturing facility will be committed to clinical and commercial manufacturing as well as development services for cell and gene therapies.

It is expected that the new facility will open in 2023.

Asian site expansion:

The investment of US$23.8 million is planned to launch a center for cancer immunotherapy and somatic stem cells. The new facility consisting of an additional 4,000 sqm will be opened near to the current facility.

This expansion is planned to double the capacity of regenerative medicine for commercial manufacturing.

The new facility is set to begin its operations in October 2022.


NameMinaris Regenerative Medicine
TypeExpansion of Manufacturing Facility in Europe and Asia
BudgetUS$64.5 million
YearEuropean Site Expansion (2023), Asian site expansion (2022)
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference